Background: There has been reported that the association between nodal spread and tumor size was disrupted in triple-negative breast cancer (TNBC) and it showed characteristically early relapse. The TNM (tumor-node-metastasis) staging system might not be equally effective as a prognostic indicator for all subtypes. The aim of our study was to evaluate the usefulness of the staging according to subtypes.
introduction
The American Joint Committee on Cancer (AJCC) TNM (tumor-node-metastasis) staging system was developed in 1959 and continued to be updated reflecting nonanatomical information based on understanding biology in order to maintain clinical relevance. It reflects the most up-to-date clinical research and widespread consensus about appropriate diagnostics and treatment standards. A major challenge to TNM staging is the rapid evolution of understanding in cancer biology and availability of biologic factors that predict cancer outcome and that response to treatment with better accuracy than that of purely anatomical-based staging [1, 2] . Rapid advance in both clinical and laboratory science and in translational research has raised questions about the ongoing relevance of TNM staging, especially in breast cancer [1] . However, its utility as prognostic indicator, rather than a predictive factor to guide specific therapy, remains its main value in current clinical practice.
Recent advances in our understanding of breast cancer biology based on molecular techniques allow us to divide breast cancer into at least five subtypes [3, 4] . Different therapeutic approaches based on the predictive markers of each subtype are needed; however, the TNM staging system still regards breast cancer as a single disease entity. Therefore, we questioned whether the TNM staging system is as valuable in the context of different breast cancer subtypes as it was in the 'pre-molecular era'.
Data from a few studies have shown that the expected association between tumor size and the number of positive axillary lymph nodes is disrupted in patients with BRCA1-related breast carcinoma [2, 3] . These BRCA1-related breast cancers share distinct gene expression profiles with basal-like breast cancer (BLBC) [4, 5] . Furthermore, many reports have revealed many similarities among BLBC, BRCA1-related breast cancer, and triple-negative breast cancer (TNBC), including morphologic, phenotypic, and genetic backgrounds [6] [7] [8] . These findings suggest that the basic biological background of TNBC differs significantly from that of non-TNBC. It has also been reported that TNBC has a distinctive pattern of recurrence, with most cases occurring within 2-3 years after diagnosis [3, [9] [10] [11] . Recently, a few reports have demonstrated original article that TNBC has a different 'radiologic phenotype', which may be easily missed in routine radiologic procedures, resulting in a misunderstanding of the objective disease extent in terms of clinical staging [12] [13] [14] . This disruption of the association between nodal spread and tumor size and the characteristic early relapse of TNBC suggests that the utility of the AJCC TNM staging system should be questioned or awarded a lower significance, particularly in TNBC subtype. Given the consistent trend of a relatively poor prognosis irrespective of nodal status in TNBC cases [15] [16] [17] , it is important to assess whether the current staging system reflects the characteristic course of TNBC. Thus, we need to determine whether the AJCC TNM staging system can function as milestone in therapeutic decision making for each breast cancer subtype. Our aim in this study was to evaluate clinical utility of the TNM staging system according to breast cancer subtypes. Additionally, we assessed whether the TNM staging system could function as an independent prognostic indicator for predicting long-term clinical outcomes for each subtype.
patients and methods
patients
We conducted a retrospective analysis of medical records of patients with histologically confirmed invasive breast cancer who received curative surgery at Samsung Medical Center from January 2000 to December 2004. At the time of diagnosis, staging work-up included history and physical examination, complete blood counts, blood chemistry, chest X-ray, bilateral mammography, ultrasound of breast if needed, and pathology examination including estrogen receptor (ER), progesterone receptor (PgR), and HER2 status. Tumor markers (CEA and CA15-3), breast magnetic resonance imaging, bone scan, and other imaging studies such as ultrasonography of upper abdomen or chest/abdominal computed tomography (CT) scan or positron emission tomography-CT scan were carried out if indicated. All pathologic specimens were reviewed by two experienced pathologists who determined the following tumor characteristics: histologic and nuclear grades, primary tumor size, presence of lymphovascular invasion, multiplicity, and the receptor status of the ER, PgR, and HER2 using immunohistochemical (IHC) staining. ER and PgR positivity was defined as an Allred score ranging from 3 to 8 by IHC using antibodies to the ER (Immunotech, Marseilles, France) and PgR (Novocastra, Newcastle, UK). HER2 status was evaluated using an antibody (DAKO) and/or FISH. Grades 0 and 1 for HER2 by IHC were defined as a negative result and grade 3 as a positive result. Amplification of HER2 was confirmed by FISH if rated 2+ by IHC. 'Triple negativity' was defined as a lack of ER, PgR, and HER2 expressions. All core biopsies from referral institutes were reviewed by experienced pathologists at our institute including IHC stainings at the time of initial referral. Pathologic reviews for all the surgical specimens were carried out prospectively and comprehensively by experienced pathologists in our institute. Our study protocol was approved by the institutional review board of Samsung Medical Center.
statistical analysis
Relapse-free survival (RFS) was defined as the time from the date of curative surgery to the date when breast cancer recurred, irrespective of locoregional recurrences including ipsilateral and contralateral breast recurrences or distant metastases. Distant recurrence-free survival (DRFS) was defined as time from the date of curative surgery to the date of documented distant metastasis. Overall survival (OS) was the time from the date of curative surgery to the date of death. RFS, DRFS, and OS were estimated by the 
clinicopathological characteristics according to subtypes
The median age at diagnosis of the patients was 46 years (range 21-82 years; 46 for HR+; 48 for HER2+; 45 for TNBC, P = 0.006 by t-test) ( Table 1) . During the median 73.3 months of follow-up, the 5-year relapse rates among the three groups were 11.9%, 30.1%, and 18.9%, respectively, and the 5-year OS rate were 94.6%, 83.1%, and 87.0%, respectively (P < 0.0001).
Higher histologic and nuclear grade were much more common in HER2+ and TNBC than they are in HR+ patients (16.9% versus 54.5% versus 70.0, P < 0.0001 for nuclear grade; 18.6% versus 53.7% versus 72.5%, P < 0.0001 for histologic grade (Figure 2A and B) . In contrast, KaplanMeier survival curves intermingled and showed overlap from stages 1 to 3A in patients with TNBC. They did not appear to be separated. A small number of patients with stages 3B and 3C disease showed the worst outcome ( Figure 2C ). There was no significant difference among the TNBC patients from stages 1 to 3A in terms of RFS ( Figure 3A) or DRFS ( Figure 3B ) with respect to stage.
RFS according to breast cancer subtypes at each TNM stage
To investigate the 'staging effect' at each TNM stage among breast cancer subtypes in terms of RFS, we compared KaplanMeier survival curves of the three subtypes. At stage 1, the HER2+ and TNBC patients had a significantly worse outcome than did the HR+ patients in terms of RFS (P < 0.0001, Figure  4A ). Stage 2 showed a similar pattern to that of stage 1 ( Figure  4B ), whereas TNBC showed a better outcome than did HER2+ group in stage 3, with an RFS curve between those of the HR+ and HER2+ patients ( Figure 4C ). When the stage 3 was analyzed in detail, patients with stage 3A TNBC had a better outcome, similar to that of HR+ patients ( Figure 4D ). The outcomes of TNBC patients with stages 3B and 3C disease were worse than that of HR+ patients and similar to that of HER2+ patients ( Figure 4E ). In order to figure out predictive factor for outcome according to stage, Cox-regression multivariate analysis was carried out at each stage ( Table 2 ). At stages 1 and 2, HER2 positivity and triple negativity were identified as independent risk factors for RFS; however, the significance was not maintained at stage 3. Limiting to stage 3A, anthracycline adjuvant chemotherapy was identified predictive factor for RFS (Hazard Ratio 0.357, P = 0.031). At stages 3B and 3C, triple negativity was a risk factor together with HER2 positivity.
adjuvant treatments and multivariate analysis on RFS in TNBC patients
In order to evaluate the effect of adjuvant treatments on longterm outcomes, we investigated adjuvant treatment at each stage for patient with TNBC. As the stage proceeded, significantly more patients received adjuvant chemotherapy or radiation therapy. Anthracyclines and taxanes adjuvant chemotherapies were administered more commonly to patients with stages 2 and 3 than was to stage 1 (Table 3) . Next, to elucidate staging effect on TNBC patients, we carried out univariate and multivariate analysis for RFS [hazard ratio 0.048, P = 0.046]. Considering merge of RFS survival KaplanMeier curves from stages 1 to 3A for TNBC patients, we limited the analysis with the population from stages 1 to 3A. Table 4 showed that adjuvant chemotherapy alone was identified as an independent prognostic factor. TNM stage did not show any prognostic significance for RFS.
discussion
The current study demonstrates that the 'AJCC TNM staging system' does not function for TNBC patients as well as it does for all breast cancer patients as a whole (Figures 2 and 3) . After excluding a small number of patients in stages 3B and 3C (n = 15, 3.8%), the four Kaplan-Meier curves of TNBC patients from stages 1 to 3A overlapped, and no significant difference could be found between them. Considering the fact that significantly more patients received adjuvant treatment including chemotherapy and radiation therapy as the stages progressed (Table 3) , there might be several heterogeneous groups of patients from stages 1 to 3A. The first group is patients who showed a definite benefit from adjuvant treatment in stage 3. When the analysis was carried out with various adjuvant chemotherapy regimens, patients with more advanced stages received anthracyclines and taxanes more commonly (Table 3) . Considering the effect of adding anthracyclines and taxanes as adjuvant chemotherapies, we could not confirm a potential benefit of either anthracyclines or taxanes. However, original article
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Cox-regression multivariate analysis except patients with stages 3B and 3C showed adding anthracyclines was an independent risk factor for RFS (Table 4) . This is a plausible explanation that there may be a patients population who had more benefit from adjuvant chemotherapy in stage 3A TNBC. The second group includes patients who relapsed because they could not receive adjuvant treatments due to low risk of relapse according to conventional treatment guidelines in early stage, and the third group consists of patients who were not affected by adjuvant treatments, due to either an indolent disease course or highly aggressive tumor behavior. Notably, adjuvant anthracycline chemotherapy alone was identified as an independent predictive factor for RFS (Table 4 ). In the case of the patients with highly aggressive tumor behavior, relapse occurred despite adjuvant treatment and irrespective of the objective tumor burden. In contrast, the patients who definitely benefited from the adjuvant treatments had a reduced risk of relapse, even in an advanced stage. Most importantly, there was no relationship between TNM staging and clinical outcome in terms of RFS for patients with TNBC. TNM staging did not provide a clear correlation between the stage of the tumor and clinical outcome across the TNBC patients. The TNM staging system did not reflect the clinical course in TNBC and could not distinguish among stages 1-3A in TNBC patients. In addition, bilaterality and multiplicity, known drawbacks of the current TNM staging system since it does not reflect complexities, were not typical findings in TNBC (Table 1 ). This suggests that TNM staging is not sufficient for predicting therapeutic outcome for TNBC patients, not because of a lack of sensitivity in the staging system but because of the completely different biology of TNBC compared with that of non-TNBC. Moreover, there was a large difference between the four overlapping KaplanMeier curves of the patients from stages 1 to 3A and the two curves of the patients in stages 3B and 3C. A steep descent in slope in order of precedence could not be found ( Figure 2C) . Here, the clinical utility of the staging was doubtful. According to our results, it was only possible to discriminate of RFS between patients with stages 1-3A and those with stages 3B-3C. The latter group included only a small proportion of all TNBC patients (3.8%). Most of the patients could not be divided according to expected clinical outcomes using the TNM staging system. At this point, a comparison of the outcomes of patients with stages 3B and 3C with those of patients with stage 4 distant metastatic diseases is needed, at least for TNBC. Furthermore, comparison among three subtypes showed that HER2+ patients with stage 3B or 3C had worse outcomes, similar to those of TNBC patients. Because our results were from the period when trastuzumab was not available for adjuvant treatment in clinical practice, the risk of relapse for these HER2 overexpressing breast cancer patients were not effectively reduced by trastuzumab. If there are any similarities between stages 3B, 3C, and 4, the adjuvant treatments and role of surgery need to be reevaluated from the beginning for this specific group of patients, even though the number of patients is small. Moreover, this result demonstrates that stage 3 of TNBC may be composed of very heterogeneous diseases that have completely different disease courses. This further indicates that the staging system is more valuable for HR+ patients than for HER2+ or TNBC patients, specifically for patients with locally advanced disease who are still regarded as ineligible by the current TNM staging system. The TNM classification was created to allow the definition of 'categories' indicating the degree of local, regional, and general extension of the disease at the time of primary treatment, thus providing a description that is objective and permanent [18] . Various categories with similar prognostic value may be grouped together to define the 'stages' of the disease [19] [20] [21] [22] . According to our results, this categorization may need to be improved for TNBC, where each stage has a different prognostic value. Thus, this grouping based on 'rigid categorization' does not function as a determinant in decision making for TNBC patients. The seventh AJCC staging system proposed that TNM staging was valuable in determining a patient's future outcome regardless of predictive role to guide whether a patient should or should not receive adjuvant endocrine or anti-HER2 therapy [1] . However, the value of TNM as a prognostic indicator for long-term clinical outcomes in TNBC could not be confirmed in our study except for a small subgroup of patients with stage IIIB or IIIC in TNBC. The seventh updated AJCC TNM staging system for breast cancer was intended to reflect underlying biology by adding a 'B' category, in which the statuses of ER, progesterone receptor, HER2, and even multigene expression profiles would be incorporated and ultimately added to the stage grouping; however, these additions ultimately added little value [1] .
As the use of targeted therapy increases, it becomes more important to classify patients according to the particular biomarker profiles for which specific treatment protocols are available [3, 4, 23] . In this regard, TNBC needs to be further studied to identify definite target biomarkers that may reflect [12-14, 24, 25] . Breast cancer classification based on gene expression profiling or IHC characteristics can support traditional histopathological classification because these approaches may be more relevant tools for matching a specific disease type with the most appropriate treatment protocol. In the near future, appropriate biomarkers based on underlying biology should be developed for TNBC. Eventually, an updated staging system that more accurately reflects outcomes needs to be developed. Once the problems of standardization and reproducibility of biomarkers are resolved, these could be incorporated into the AJCC staging system. Given the condition that current staging system hardly adapts to TNBC subtypes as it is, at first, we should not apply it as rigid categorization to decide further adjuvant treatments as in other subtypes of tumors. Then, we prospect that new modified staging system may have more appropriate clinical relevance in TNBCs to decide adjuvant treatments, if the development of biomarker could incorporate into new innovative targeted therapy. Therefore, the development of robust biomarkers to predict characteristic clinical outcomes based on biologic behaviors needs to be implemented in new modified staging system. In conclusion, the currently used TNM staging system, which represents objective tumor burden at surgery, might not be sufficient for categorizing the tumor biology and for predicting clinical outcomes in order to make therapeutic decisions for all breast cancers, in particular for TNBC patients. 
